Levofloxacin (sodium)

Levofloxacin ((-) -Ofloxacin) sodium is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin sodium inhibits the DNA gyrase and topoisomerase IV. Levofloxacin sodium can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin sodium shows anti-orthopoxvirus activity[1][2][3][4][5].

Product Specifications

CAS Number

[872606-49-0]

Product Name Alternative

(-) -Ofloxacin (sodium)

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Antibiotic; Bacterial; DNA/RNA Synthesis; Orthopoxvirus; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/levofloxacin-sodium.html

Solubility

10 mM in DMSO

Smiles

O=C1C2=CC(F)=C(N3CCN(CC3)C)C4=C2N(C=C1C(O[Na])=O)[C@@H](C)CO4

Molecular Formula

C18H19FN3NaO4

Molecular Weight

383.35

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57 (1-2) :41-52.|[2]Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86.|[3]Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014.|[4]Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014.|[5]Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61 (3) :377-92.